Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label dose-finding study of oral BI 853520 in advanced solid tumors
NL-OMON39828Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ifebemtinib in Nonhematologic neoplasms and cancer, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicities. Started Jul 2011; status: active, not recruiting.
02
Drugs
ifebemtinib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON39828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39828.